GlassScriptPhysician profile
David R Ralston
NPI 1164408472
$31,643.24
in general payments reported to CMS, 2019-2025
29 companies · $537 in 2025
The $537 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,103 · 2020: $6,049 · 2021: $3,995 · 2022: $4,332 · 2023: $5,334 · 2024: $5,293 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,856 · Food and Beverage: $1,887 · Consulting Fee: $300 · Travel and Lodging: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,856.00 |
| Food and Beverage | $1,886.74 |
| Consulting Fee | $300.00 |
| Travel and Lodging | $120.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $28,183.59 | 2019-2024 | Yupelri, Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $658.20 | 2019-2024 | Spiriva Respimat, Ofev |
| Genzyme Corporation | $625.94 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $404.21 | 2022-2025 | |
| Glaxosmithkline, LLC. | $269.29 | 2021-2025 | Nucala |
| Astrazeneca Pharmaceuticals LP | $222.05 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Avadel Cns Pharmaceuticals, LLC | $197.21 | 2023-2024 | Lumryz |
| Grifols USA, LLC | $191.91 | 2019-2025 | Prolastin-C Liquid |
| Insmed, INC. | $113.93 | 2022-2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $86.48 | 2023-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $86.36 | 2021-2024 | Recarbrio, Zerbaxa, Keytruda |
| Harmony Biosciences LLC | $61.16 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.46 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $50.62 | 2023-2024 | Opsumit, Uptravi |
| Zoll Respicardia, INC. | $50.55 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $49.56 | 2023-2024 | Tyvaso |
| Paratek Pharmaceuticals, INC. | $47.09 | 2023 | Nuzyra |
| Fisher & Paykel Healthcare INC | $40.63 | 2025 | Fisher & Paykel Healthcare |
| Pfizer INC. | $34.64 | 2024 | |
| Amgen INC. | $32.88 | 2024 | Tezspire |
| Idorsia Pharmaceuticals US INC | $28.88 | 2023-2024 | Quviviq |
| Philips North America LLC | $28.85 | 2022-2023 | |
| Resmed Corp | $25.78 | 2025 | |
| Baxter Healthcare | $24.84 | 2024 | Hillrom - Vest System Model 105 Home Care |
| 3b Medical, INC. | $18.99 | 2024 | Luna |
| Abbvie INC. | $17.52 | 2022 | |
| Covis Pharma Gmbh | $15.35 | 2022 | |
| Gilead Sciences, INC. | $13.66 | 2023 | |
| Genentech USA, INC. | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ralston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.